308 related articles for article (PubMed ID: 30460522)
1. A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.
Conner TM; Reed RC; Zhang T
Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):389-408. PubMed ID: 30460522
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T
Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
Brittain ST; Wheless JW
Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.
Polepally AR; Remmel RP; Brundage RC; Leppik IE; Rarick JO; Ramsay RE; Birnbaum AK
J Clin Pharmacol; 2015 Oct; 55(10):1101-8. PubMed ID: 25903807
[TBL] [Abstract][Full Text] [Related]
5. Development of physiologically based pharmacokinetic model to evaluate the relative systemic exposure to quetiapine after administration of IR and XR formulations to adults, children and adolescents.
Johnson TN; Zhou D; Bui KH
Biopharm Drug Dispos; 2014 Sep; 35(6):341-52. PubMed ID: 24797229
[TBL] [Abstract][Full Text] [Related]
6. Steady-state pharmacokinetics of lamotrigine when converting from a twice-daily immediate-release to a once-daily extended-release formulation in subjects with epilepsy (The COMPASS Study).
Tompson DJ; Ali I; Oliver-Willwong R; Job S; Zhu L; Lemme F; Hammer AE; Vuong A; Messenheimer JA
Epilepsia; 2008 Mar; 49(3):410-7. PubMed ID: 17825077
[TBL] [Abstract][Full Text] [Related]
7. Lacosamide extended-release capsules are bioequivalent to lacosamide immediate-release tablets: Pharmacokinetic observations and simulations.
Wheless J; Gidal B; Gong L; Lyu S; Zheng X; Li R; Chang W; Tan M
Epilepsy Res; 2024 May; 202():107350. PubMed ID: 38513537
[TBL] [Abstract][Full Text] [Related]
8. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation.
Chen C; Wright J; Gidal B; Messenheimer J
Ther Drug Monit; 2013 Apr; 35(2):188-93. PubMed ID: 23503444
[TBL] [Abstract][Full Text] [Related]
9. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of a novel extended-release metformin formulation.
Timmins P; Donahue S; Meeker J; Marathe P
Clin Pharmacokinet; 2005; 44(7):721-9. PubMed ID: 15966755
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release.
Ermer JC; Shojaei A; Pennick M; Anderson CS; Silverberg A; Youcha SH
Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073
[TBL] [Abstract][Full Text] [Related]
12. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates.
Arora S; Pansari A; Kilford PJ; Jamei M; Turner DB; Gardner I
Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):483-495. PubMed ID: 35486324
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Drug-Drug Interaction Liability for Buprenorphine Extended-Release Monthly Injection Administered by Subcutaneous Route.
Kharidia J; Howgate EM; Laffont CM; Liu Y; Young MA
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1064-1074. PubMed ID: 33750027
[TBL] [Abstract][Full Text] [Related]
14. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
15. Modified-Release Formulations of Second-Generation Antiepileptic Drugs: Pharmacokinetic and Clinical Aspects.
Anderson GD; Saneto RP
CNS Drugs; 2015 Aug; 29(8):669-81. PubMed ID: 26369919
[TBL] [Abstract][Full Text] [Related]
16. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
[TBL] [Abstract][Full Text] [Related]
17. Conversion from immediate-release to extended-release lamotrigine improves seizure control.
Ramey P; Osborn M; Abou-Khalil B
Epilepsy Res; 2014 Nov; 108(9):1637-41. PubMed ID: 25205163
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
19. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation.
Bialer M; Shekh-Ahmad T; Braun TL; Halvorsen MB
Epilepsia; 2013 Aug; 54(8):1444-52. PubMed ID: 23692553
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Tolerability of Lamotrigine Chewable/Dispersible Tablet Following Repeat-Dose Administration in Healthy Chinese Volunteers.
Li Y; Zhang F; Xu Y; Hu J; Li H
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):627-633. PubMed ID: 29578646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
